12 January 2026: Independence, OH – Great Lakes NeuroTechnologies (GLNT) is excited to announce that it has been awarded US Patent 12,502,121, “Artificial intelligence systems for quantifying movement disorder symptoms and adjusting treatment based on symptom quantification.” This patent describes the use of artificial intelligence (AI) to measure the severity and characteristics of symptoms associated with movement disorders, such as Parkinson’s disease (PD) and essential tremor (ET), and automatically adjust or provide recommendations for treatment based on the symptom measurements.
According to GLNT President and COO, Dustin Heldman, “We have been the leader in remote patient monitoring of movement disorders for many years. With our Kinesia technology, doctors can track how their patients’ motor symptoms respond to therapy. This new patent will help our company build upon our extensive patient monitoring capabilities and become an important part of disease management. We firmly believe doctors will always be part of the decision-making process. Initially, the system could provide recommendations to doctors, but eventually, this could lead to fully automated therapy decision-making and adjustment, with doctors only needing to supervise and approve.”
About Great Lakes NeuroTechnologies
Great Lakes NeuroTechnologies [ www.GLNeuroTech.com ] is committed to pioneering innovative biomedical technologies to serve research, education, and medical communities, improving access to medical technology for diverse populations, and positively impacting quality of life for people around the world.
About Kinesia™ Technology
GLNT commercialized Kinesia™ technology to provide wearable, objective, and automated assessment of movement disorders such as Parkinson’s disease and essential tremor. The clinically validated technology has been adopted by many of the world’s leading pharmaceutical and medical device companies as the standard for objective sensor measurement for movement disorders. The KinesiaU™ motor assessment system is a validated, low-cost prescription medical app for individuals to measure their Parkinson’s disease and essential tremor symptoms using an iPhone or Android smartphone and smartwatch. The KinesiaU system tracks tremors, slowness, and dyskinesia as well as therapies and activities in user-friendly reports. These can help patients and clinicians make better care decisions and identify therapies and activities to improve their symptoms.
The Kinesia family of motor assessment systems are approved in many regions around the world, but due to individual country regulations, such as language translations, data restrictions, and other regulatory requirements, specific Kinesia products lines may not be approved or available and therefore should not be used in those locations. The Kinesia technology is patented in the US, India, and various countries in Europe including the UK (see https://www.glneurotech.com/patents).
Media Relations
Great Lakes NeuroTechnlogies 1-216-361-5410 media@glneurotech.com